Epigenetics in Psychiatry, Second Edition covers all major areas of psychiatry in which extensive epigenetic research has been performed, fully encompassing a diverse and maturing field, including drug addiction, bipolar disorder, epidemiology, cognitive disorders, and the uses of putative epigenetic-based psychotropic drugs. Uniquely, each chapter correlates epigenetics with relevant advances across genomics, transcriptomics, and proteomics. The book acts as a catalyst for further research in this growing area of psychiatry. This new edition has been fully revised to address recent advances in epigenetic understanding of psychiatric disorders, evoking data consortia (e.g., CommonMind, ATAC-seq), single cell analysis, and epigenome-wide association studies to empower new research. The book also examines epigenetic effects of the microbiome on psychiatric disorders, and the use of neuroimaging in studying the role of epigenetic mechanisms of gene expression. Ongoing advances in epigenetic therapy are explored in-depth. - Fully revised to discuss new areas of research across neuronal stem cells, cognitive disorders, and transgenerational epigenetics in psychiatric disease - Relates broad advances in psychiatric epigenetics to a modern understanding of the genome, transcriptome, and proteins - Catalyzes knowledge discovery in both basic epigenetic biology and epigenetic targets for drug discovery - Provides guidance in research methods and protocols, as well how to employ data from consortia, single cell analysis, and epigenome-wide association studies (EWAS) - Features chapter contributions from international leaders in the field

Neuropsychiatric Disorders and Epigenetics, Second Edition is a comprehensive reference on the epigenetic basis of common neuropsychiatric disorders. The volume is organized into chapters covering individual neuropsychiatric disorders, from addiction to anxiety and autism spectrum disorders, and is contributed by leading experts in their respective fields. The epigenetic aspects of each disorder are discussed, in the context of the full range of associated epigenetic mechanisms, including DNA modification, histone post-translational modification, chromatin organization, and non-coding RNA. A particular emphasis is placed on potential epigenetic interventions, when the effects of environmental stimuli on epigenetic states is particularly relevant to disease.This new edition has been fully updated to reflect recent research advances enabled by genomic technologies, as well as therapeutic interventions for previously unmanageable disorders. Several new chapters have been added on disorders or approaches not considered in the earlier edition, including epigenetics and anxiety disorders, epigenetics and neuroimaging in neuropsychiatric disorders, genome-wide approaches to epigenetic research, and the epigenetics of spinal muscular atrophy. By helping to define epigenetics as a key player in neuropsychiatric disorders, this volume empowers new research, clinical translation, and pharmacological advances, and highlights promising directions for ongoing investigation. - Analyzes the effects of environmental stimuli on epigenetic states that correlate with neuropsychiatric disease induction - Reviews the epigenetic basis for common neuropsychiatric disorders, thereby guiding translational therapies for clinicians and mechanistic studies for scientists - Features extensive use of diagrams, illustrations, tables, and graphical abstracts for each section to reinforce understanding - - Includes chapter contributions from leading global experts

Psychiatric Genetics: A Primer for Clinical and Basic Scientists offers a straightforward introduction to the essentials of psychiatric genetics, covering basic epidemiology, recruitment for human studies, phenotyping strategies, formal genetic and molecular genetic studies, statistical genetics, bioinformatics and genomics, pharmacogenetics, the most relevant animal models, and biobanking. Each chapter begins with a list of "take home" points that summarizes content, followed by a brief overview of current knowledge and suggestions for further reading.

The 2nd edition of this book incorporates the tremendous clinical advances that have occurred in the field of transcranial direct current stimulation (tDCS) over the past 5 years. Since the 1st edition was published, the clinical use of tDCS has moved from its infancy, and is now in a thrilling new phase with numerous possibilities as well as challenges. tDCS is a technique that excels in terms of safety and tolerability, and within a few years, novel technological developments will allow its use at home. At the same time, large, phase III trials have been exploring the clinical efficacy of tDCS, the results of which have been published in leading journals such as the New England Journal of Medicine and JAMA Psychiatry. This 2nd edition summarizes the state of the art of the field. Written by leading experts in the field, the book is divided into 5 parts: Introduction and Mechanisms of Action; Research Methods; tDCS in the life cycle; Applications of tDCS in neuropsychiatric disorders (further divided into Psychiatry and Neurology); and The clinical use of tDCS. It also includes several new chapters, covering topics such as precision stimulation of tDCS; combination of tDCS with different neuroimaging modalities; and use of tDCS in new clinical conditions. Moreover, all chapters have been rewritten and updated. This book will be of significant interest to psychiatrists, neurologists and neuroscientists new to the field as well as those with a background in tDCS who want to increase their understanding of particular psychiatric conditions.

The understanding of how to reduce risk factors for mental disorders has expanded remarkably as a result of recent scientific advances. This study, mandated by Congress, reviews those advances in the context of current research and provides a targeted definition of prevention and a conceptual framework that emphasizes risk reduction. Highlighting opportunities for and barriers to interventions, the book draws on successful models for the prevention of cardiovascular disease, injuries, and smoking. In addition, it reviews the risk factors associated with Alzheimer's disease, schizophrenia, alcohol abuse and dependence, depressive disorders, and conduct disorders and evaluates current illustrative prevention programs. The models and examination provide a framework for the design, application, and evaluation of interventions intended to prevent mental disorders and the transfer of knowledge about prevention from research to clinical practice. The book presents a focused research agenda, with recommendations on how to develop effective intervention programs, create a cadre of prevention researchers, and improve coordination among federal agencies.

The Massachusetts General Hospital is widely regarded as one of the world's premier psychiatric institutions. Massachusetts General Hospital Comprehensive Clinical Psychiatry, 3rd Edition, offers practical, informative, and hands-on advice from the staff of the esteemed MGH Department of Psychiatry, helping you put today's best practices to work for your patients. This authoritative reference covers a wide variety of clinical syndromes and settings, aided by superb graphics throughout. In one convenient volume, you'll have easy access to the answers you need to face and overcome any clinical challenge. - Uses a reader-friendly and highly templated format with abundant boxed summaries, bulleted points, case histories, algorithms, references, and suggested readings. - Contains new chapters on the Psychiatric Management of Patients with Cardiac, Renal, Pulmonary, and Gastrointestinal Disease; COVID-19 Infection; Burns, Trauma, and Intensive Care Unit Treatment; Care of LGBTQ Patients; and Mindfulness and Resilience. - Covers key areas, such as Substance Use Disorders; Mood, Anxiety, and Psychotic Disorders; Emergency Psychiatry; Functional Neuroanatomy and the Neurologic Examination; Psychological and Neuropsychological Assessment; Military Psychiatry; Psychiatric Manifestations of Traumatic Brain Injury; Legal and Ethical Issues in Psychiatry; End of Life Care; and Approaches to Collaborative Care and Primary Care Psychiatry. - Features key points for every chapter, updated DSM-5 criteria, and enhanced content on collaborative care and behavioral medicine, ensuring that your knowledge is thorough and up to date. - Corresponds to the companion review volume, Massachusetts General Hospital Study Guide for Psychiatry Exams, 2nd Edition (ISBN: 978-0-443-11983-5). - Any additional digital ancillary content may publish up to 6 weeks following the publication date.

Neuropsychiatric diseases, such as schizophrenia, Alzheimer's disease, and etc., represent a serious medical and socioeconomic problems. These diseases are often accompanied by impairments of cognitive function, e.g., abstract thinking, decision-making, attention, and several types of memory. Such deficits significantly disrupt quality of life and daily functioning of patients. Cognitive deficits in neuropsychiatric diseases are associated with alterations of brain morphology and function, and are often resistant to therapeutic interventions. In schizophrenia and related disorders, cognitive deficits are also defined as endophenotypes, i.e. measurable phenotypes linking these disaeses with discrete heritable and reproducible traits. This points to the importance of elucidating these endophenotypes in translational studies. Animal models may not mimic the full spectrum of clinical symptoms, but may act as analogies of particular behaviors or other pathological outcomes. They are useful to search for the etiology of particular psychiatric illnesses and novel therapeutics. Moreover, several behavioral tests to measure cognitive performance in rodents and other species have been implemented. The primary focus of the present topic is to provide up-to-date information on cognitive deficits of neuropsychiatric disorders, such as schizophrenia. This Research Topic also delineates future directions for translational studies aimed at developing novel treatments/interventions of cognitive disturbances.

Raising hopes for disease treatment and prevention, but also the specter of discrimination and "designer genes," genetic testing is potentially one of the most socially explosive developments of our time. This book presents a current assessment of this rapidly evolving field, offering principles for actions and research and recommendations on key issues in genetic testing and screening. Advantages of early genetic knowledge are balanced with issues associated with such knowledge: availability of treatment, privacy and discrimination, personal decision-making, public health objectives, cost, and more. Among the important issues covered: Quality control in genetic testing. Appropriate roles for public agencies, private health practitioners, and laboratories. Value-neutral education and counseling for persons considering testing. Use of test results in insurance, employment, and other settings.